Astria Therapeutics, Inc. (ATXS) |
|
8.53 0.15 (1.79%)
|
09-27 11:07 |
|
Open: |
8.44 |
Pre. Close: |
8.38 |
|
High:
|
8.815 |
Low:
|
8.385 |
|
Volume:
|
43,902 |
Market Cap:
|
239(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 10:45:18 AM |
|
Short-term rate:
|
  |
| Stoxline posted a BUY today, downgraded from strong buy. Upward movement continues, but could change at any time. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 10.86 One year: 12.68 |
| Support: |
Support1: 7.71 Support2: 6.73 |
| Resistance: |
Resistance1: 9.3 Resistance2: 10.86 |
| Pivot: |
8.04 |
| Moving Average: |
MA(5): 7.7 MA(20): 8.26
MA(100): 9.61 MA(250): 10.97 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 64.7 %D(3): 41.8 |
| RSI: |
RSI(14): 55.4 |
| 52-week: |
High: 16.28 Low: 6.73 |
| Average Vol(K): |
3-Month: 175 (K) 10-Days: 126 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ATXS ] has closed below upper band by 28.5%. Bollinger Bands are 23.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
8.47 - 8.51 |
8.51 - 8.54 |
|
Low:
|
7.46 - 7.5 |
7.5 - 7.53 |
|
Close:
|
8.32 - 8.38 |
8.38 - 8.45 |
|
Company Description |
|
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts. |
Headline News |
Wed, 06 Sep 2023
Astria Therapeutics to Participate in Upcoming Investor Conferences - Business Wire
Thu, 31 Aug 2023
Astria Therapeutics Announces Publication of STAR-0215 ... - Business Wire
Tue, 29 Aug 2023
Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Declines ... - MarketBeat
Mon, 07 Aug 2023
Astria Therapeutics Reports Second Quarter Financial Results and ... - Business Wire
Wed, 02 Aug 2023
Astria Therapeutics Announces Inducement Grants Under Nasdaq ... - Business Wire
Thu, 20 Jul 2023
Astria Therapeutics Receives Fast Track Designation for STAR-0215 ... - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
28 (M) |
| Shares Float |
20 (M) |
|
% Held by Insiders
|
0.9 (%) |
|
% Held by Institutions
|
87.4 (%) |
|
Shares Short
|
880 (K) |
|
Shares Short P.Month
|
1,030 (K) |
Stock Financials |
|
EPS
|
-2.15 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
3.75 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-22.2 |
|
Return on Equity (ttm)
|
-32.8 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-45 (M) |
|
Levered Free Cash Flow
|
-29 (M) |
Stock Valuations |
|
PE Ratio
|
-4.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
2.28 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-5.37 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
